Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Acorda Therapeutics
Most Recent Events
- 09 Nov 2015 Post-hoc subgroup analysis results published in the Clinical Therapeutics
- 23 Mar 2013 Results presented at the 65th Annual Meeting of the American Academy of Neurology.
- 13 Mar 2013 Subgroup analysis presented at the the 65th American Academy of Neurology Annual Meeting (AAN-2013), according to an Acorda Therapeutics media release.